Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

May 19, 2021

Study Completion Date

June 30, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Pembrolizumab

pembrolizumab 200mg IV every three weeks

DEVICE

Y90 radioembolization

The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).

Trial Locations (3)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

98109

University of Washington/Fred Hutchinson Cancer Research Center, Seattle

27599-7097

The University of North Carolina at Chapel Hill, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Hoosier Cancer Research Network

OTHER

lead

Ashwin Somasundaram

OTHER